How can we improve deprescribing communication among patients with dementia and multiple chronic conditions?
A qualitative study in primary care lends key insights.
Green AR, et al. Designing a Primary Care-Based Deprescribing Intervention for Patients with Dementia and Multiple Chronic Conditions: A Qualitative Study. J Gen Intern Med.
Application to form a Special Interest Group
The US Deprescribing Research Network seeks applicants to form special interest groups (SIGs) in order to encourage networking and collaboration on specific projects. These member-led
Now accepting applications: Junior Investigator Intensive Program
Apply now to be part of USDeN’s next cohort of Junior Investigator Intensive Program participants! The program will create a cohort of emerging leaders who
New site selected for Data Harmonization Working Group
We are pleased to announce that Drs. Sean Hennessy and Allison Willis from the University of Pennsylvania will represent the 5th site for the Data
When it’s better to stop or decrease health care services and interventions: researchers bring validity and transparency to deintensification recommendations in primary care.
Kerr EA, et al. Identifying recommendations for stopping or scaling back unnecessary routine services in primary care. JAMA Intern Med. 2020;180(11):1500-1508. doi:10.1001/jamainternmed.2020.4001 A recent study
2020-2021 Network Grantees Selected
We are pleased to announce our 2020-2021 cohort of network grantees. Six projects, including 2 grant planning and 4 pilots are underway.
Which Outcome Measures are Most Commonly Used in Deprescribing Interventions?
Aubert C, et al. Outcome Measures for Interventions to Reduce Inappropriate Chronic Drugs: A Narrative Review. J Am Geriatr Soc. 2020; doi: 10.1111/jgs.16697 A new
The OPTIMISE Randomized Clinical Trial: Deprescribing Antihypertensive Medications in Adults Aged 80 and Older and its Effect on Blood Pressure
Sheppard J, et al. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients with Hypertension Aged 80 Years and
Junior Investigators Selected for Intensive in Deprescribing Research!
We are very pleased to announce our 2020-2021 cohort of Junior Investigator Intensive Awardees. The Junior Investigator Intensive program provides dedicated supports and research learning
Two new AD/ADRD-related RFAs from the IMPACT Collaboratory
The IMPACT Collaboratory released two new Requests for Applications (RFAs) for conducting pragmatic trials in persons with AD/ADRD on April 20: Request for Applications for
